• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于评估光化性角化病疾病严重程度分级的新型光化性角化病皮损评估量表。

A Novel Actinic Keratosis Field Assessment Scale for Grading Actinic Keratosis Disease Severity.

作者信息

Dréno Brigitte, Cerio Rino, Dirschka Thomas, Nart Ignasi Figueras, Lear John T, Peris Ketty, de Casas Andrés Ruiz, Kaleci Shaniko, Pellacani Giovanni

机构信息

Department of Dermato Cancereology, University of Nantes, FR-44093 Nantes, France.

出版信息

Acta Derm Venereol. 2017 Oct 2;97(9):1108-1113. doi: 10.2340/00015555-2710.

DOI:10.2340/00015555-2710
PMID:28536731
Abstract

Actinic keratosis (AK) lesions are surrounded by field cancerization (areas of subclinical, non-visible sun damage). Existing AK grading tools rely on AK counts, which are not reproducible. An Actinic Keratosis Field Assessment Scale (AK-FAS) for grading the severity of AK/field was developed. Standardized photographs of patients representing the full range of AK severity were collected. Six investigators independently rated each photograph according to 3 criteria: AK area (total skin area affected by AK lesions), hyperkeratosis and sun damage. Inter-rater reproducibility was good for all 3 criteria. Validation of the AK-FAS showed good reproducibility for AK area and hyperkeratosis, even for dermatologists untrained on use of the scale. In conclusion, the AK-FAS is objective, easy to use and implement, and reproducible. It incorporates assessment of the entire field affected by AK instead of relying on lesion counts. Use of the AK-FAS may standardize AK diagnosis, making it relevant to routine clinical practice.

摘要

光化性角化病(AK)皮损被场癌化(亚临床、不可见的日光损伤区域)所包围。现有的AK分级工具依赖于AK计数,而这是不可重复的。一种用于对AK/场的严重程度进行分级的光化性角化病场评估量表(AK-FAS)被开发出来。收集了代表AK严重程度全范围的患者标准化照片。六位研究者根据三个标准独立对每张照片进行评分:AK面积(受AK皮损影响的总皮肤面积)、角化过度和日光损伤。所有三个标准的评分者间再现性良好。AK-FAS的验证表明,即使对于未接受过该量表使用培训的皮肤科医生,AK面积和角化过度的再现性也很好。总之,AK-FAS客观、易于使用和实施,且具有可重复性。它纳入了对受AK影响的整个区域的评估,而不是依赖于皮损计数。AK-FAS的使用可能会使AK诊断标准化,使其与常规临床实践相关。

相似文献

1
A Novel Actinic Keratosis Field Assessment Scale for Grading Actinic Keratosis Disease Severity.一种用于评估光化性角化病疾病严重程度分级的新型光化性角化病皮损评估量表。
Acta Derm Venereol. 2017 Oct 2;97(9):1108-1113. doi: 10.2340/00015555-2710.
2
Efficacy of a photolyase-based device in the treatment of cancerization field in patients with actinic keratosis and non-melanoma skin cancer.基于光解酶的设备在治疗光化性角化病和非黑素瘤皮肤癌患者癌前病变中的疗效。
G Ital Dermatol Venereol. 2013 Dec;148(6):693-8.
3
Defining the actinic keratosis field: a literature review and discussion.定义光化性角化病的病灶:文献回顾与讨论。
J Eur Acad Dermatol Venereol. 2018 Apr;32(4):544-563. doi: 10.1111/jdv.14652. Epub 2017 Nov 24.
4
A proposed scoring system for assessing the severity of actinic keratosis on the head: actinic keratosis area and severity index.一种用于评估头部光化性角化病严重程度的评分系统:光化性角化病面积和严重指数。
J Eur Acad Dermatol Venereol. 2017 Aug;31(8):1295-1302. doi: 10.1111/jdv.14267. Epub 2017 May 3.
5
Effects of topical piroxicam and sun filters in actinic keratosis evolution and field cancerization: a two-center, assessor-blinded, clinical, confocal microscopy and dermoscopy evaluation trial.吡罗昔康和防晒剂对光化性角化病进展和癌前病变的影响:一项双中心、评估者盲法、临床、共聚焦显微镜和皮肤镜评估试验。
Curr Med Res Opin. 2019 Oct;35(10):1785-1792. doi: 10.1080/03007995.2019.1626227. Epub 2019 Jun 13.
6
Long-term sustained lesion clearance from Lmax with imiquimod 3.75%, a new field-directed treatment for actinic keratosis.长期使用咪喹莫特 3.75%持续清除 Lmax 病变,一种新的光化性角化病的定向治疗方法。
J Eur Acad Dermatol Venereol. 2015 Sep;29(9):1840-2. doi: 10.1111/jdv.12697. Epub 2014 Aug 29.
7
Vascular feature identification in actinic keratosis grades I-III using dynamic optical coherence tomography with automated, quantitative analysis.使用具有自动定量分析功能的动态光学相干断层扫描技术对 I-III 级光化性角化病的血管特征进行识别。
Arch Dermatol Res. 2024 Jun 15;316(7):391. doi: 10.1007/s00403-024-03022-z.
8
Efficacy of a film-forming medical device containing sunscreen (50+) and piroxicam 0.8% in actinic keratosis and field cancerization: a multicenter, assessor-blinded, 3 month trial.一种含有防晒霜(防晒指数50+)和0.8%吡罗昔康的成膜医疗设备治疗光化性角化病和场癌化的疗效:一项多中心、评估者盲法的3个月试验。
Curr Med Res Opin. 2017 Jul;33(7):1255-1259. doi: 10.1080/03007995.2017.1313212. Epub 2017 Apr 20.
9
Efficacy of imiquimod 3.75% from Lmax according to the number of actinic keratosis lesions.根据光化性角化病皮损数量,来自Lmax的3.75%咪喹莫特的疗效。
J Eur Acad Dermatol Venereol. 2015 Dec;29(12):2470-3. doi: 10.1111/jdv.12782. Epub 2014 Oct 28.
10
Expert Consensus on Cosmetic Outcomes After Treatment of Actinic Keratosis.光化性角化病治疗后美容效果的专家共识
J Drugs Dermatol. 2017 Mar 1;16(3):260-264.

引用本文的文献

1
Real-World Efficacy of Tirbanibulin in Actinic Keratosis Treatment: Expert Consensus and Clinical Insights.替拉瑞林治疗光化性角化病的真实世界疗效:专家共识与临床见解
Dermatol Pract Concept. 2025 Jul 31;15(3):5921. doi: 10.5826/dpc.1503a5921.
2
Self-Applied Daylight Photodynamic Therapy: A Paradigm Shift?自我应用日光光动力疗法:一种范式转变?
Int J Mol Sci. 2025 Jan 13;26(2):628. doi: 10.3390/ijms26020628.
3
Clinical and Dermoscopic Comparison of the Efficacy and Safety of 5% Fluorouracil Topical Cream and 1% Niacinamide Topical Gel in the Treatment of Actinic Keratosis: A Randomized Controlled Trial.
5%氟尿嘧啶外用乳膏与1%烟酰胺外用凝胶治疗光化性角化病疗效及安全性的临床与皮肤镜比较:一项随机对照试验
J Cosmet Dermatol. 2025 Feb;24(2):e16676. doi: 10.1111/jocd.16676. Epub 2024 Nov 26.
4
Actinic keratosis metrics.光化性角化病计量学。
Arch Dermatol Res. 2024 Aug 20;316(8):543. doi: 10.1007/s00403-024-03305-5.
5
Dynamic optical coherence tomography unveils subclinical, vascular differences across actinic keratosis grades I-III.动态光学相干断层扫描揭示了 I-III 级光化性角化病各等级的亚临床血管差异。
Exp Dermatol. 2024 Aug;33(8):e15153. doi: 10.1111/exd.15153.
6
Clinical and Dermoscopic Diagnosis of Actinic Keratosis.光化性角化病的临床与皮肤镜诊断
Dermatol Pract Concept. 2024 Jul 1;14(3 S1):e2024147S. doi: 10.5826/dpc.1403S1a147S.
7
Epidemiology and Risk Factors of Actinic Keratosis. What is New for The Management for Sun-Damaged Skin.光化性角化病的流行病学与危险因素。日光损伤皮肤管理的新进展。
Dermatol Pract Concept. 2024 Sep 1;14(3 S1):e2024146S. doi: 10.5826/dpc.1403S1a146S.
8
An Update on Non-Invasive Skin Imaging Techniques in Actinic Keratosis-A Narrative Review.光化性角化病的无创性皮肤成像技术更新:综述
Medicina (Kaunas). 2024 Jun 26;60(7):1043. doi: 10.3390/medicina60071043.
9
Digitally Enhanced Methods for the Diagnosis and Monitoring of Treatment Responses in Actinic Keratoses: A New Avenue in Personalized Skin Care.光化性角化病诊断及治疗反应监测的数字增强方法:个性化皮肤护理的新途径
Cancers (Basel). 2024 Jan 23;16(3):484. doi: 10.3390/cancers16030484.
10
Expression of p53, p63, p16, Ki67, Cyclin D, Bcl-2, and CD31 Markers in Actinic Keratosis, In Situ Squamous Cell Carcinoma and Normal Sun-Exposed Skin of Elderly Patients.p53、p63、p16、Ki67、细胞周期蛋白D、Bcl-2和CD31标志物在老年患者日光性角化病、原位鳞状细胞癌及正常暴露日光皮肤中的表达
J Clin Med. 2023 Nov 24;12(23):7291. doi: 10.3390/jcm12237291.